For the year ending 2025-12-31, EVMN made $13M in revenue. -$68.87M in net income. Net profit margin of -529.77%.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Total revenue | 13 | |||
| Research and development | 74.042 | |||
| General and administrative | 20.029 | |||
| Total operating expenses | 94.071 | |||
| Loss from operations | -81.071 | |||
| Change in fair value of convertible preferred stock forward | 8.928 | |||
| Interest income | 3.323 | |||
| Other expense, net | 0.05 | |||
| Total other income, net | 12.201 | |||
| Net loss | -68.87 | |||
| Basic EPS | -11.22 | |||
| Diluted EPS | -11.22 | |||
| Basic Average Shares | 6,136,636 | |||
| Diluted Average Shares | 6,136,636 | |||
Evommune, Inc. (EVMN)
Evommune, Inc. (EVMN)